iPS细胞来源间充质基质细胞治疗急性激素难治性移植物抗宿主病的两年安全性结局
该首次完成的诱导多能干细胞(iPS细胞)来源细胞临床试验纳入15例激素难治性急性移植物抗宿主病患者,静脉输注间充质基质细胞(CYP-001)后随访2年,9例(60%)存活,未观察到与CYP-001相关的严重不良事件、肿瘤或其他安全性问题。
要点
- 15例激素难治性急性GVHD患者输注iPS细胞来源间充质基质细胞CYP-001。
- 2年随访时9例(60%)存活,死亡原因与CYP-001治疗无关。
- 未观察到与CYP-001相关的严重不良事件、肿瘤或其他安全性问题。
核心结论
- iPS细胞来源细胞的全身输注在2年随访期间安全且耐受良好,首次输注后疗效持续至2年。
研究设计与样本
- 首个完成的iPS细胞来源细胞临床试验,纳入15例激素难治性急性移植物抗宿主病患者,静脉输注间充质基质细胞CYP-001,本次报告2年随访结果。
主要发现
- 2年随访时15例中9例(60%)存活,与此前报道的激素难治性急性移植物抗宿主病研究结局相比更为有利。
- 死亡原因均为异基因造血干细胞移植受者常见并发症,研究者认为与CYP-001治疗无关。
- 未观察到与CYP-001相关的严重不良事件、肿瘤或其他安全性问题。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The first completed clinical trial of induced pluripotent stem cell (iPS cell)-derived cells was conducted in 15 participants with steroid-resistant acute graft-versus-host disease. After intravenous infusion of mesenchymal stromal cells (CYP-001 derived from a clone of human iPS cells), we reported the safety, tolerability and efficacy within the primary evaluation period at day 100. We now report results at the 2-year follow-up: 9 of 15 (60%) participants survived, which compares favorably with previously reported outcomes in studies of steroid-resistant acute graft-versus-host disease. Causes of death were complications commonly observed in recipients of allogeneic hematopoietic stem cell transplantation, and not considered by the investigators to be related to CYP-001 treatment. There were no serious adverse events, tumors or other safety concerns related to CYP-001. In conclusion, systemic delivery of iPS cell-derived cells was safe and well tolerated over 2 years of follow-up, with sustained outcomes up to 2 years after the first infusion. ClinicalTrials.gov registration: NCT02923375 .
引用
- Kelly K, Bloor AJC, Griffin JE, et al. Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease. Nat Med. 2024. PMID: 38778211. doi:10.1038/s41591-024-02990-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。